Andreia Magalhães
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andreia Magalhães has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Fausto José Pinto
University of Lisbon
7 shared publications - Manuela Fiuza
Serviço de Cardiologia ULSSM, CAML, CCUL@RISE, FMUL, Portugal
7 shared publications - Nuno Cortez-Dias
University Hospital Santa Maria, Department of Cardiology, Lisbon Academic Medical Centre, CCUL, Lisbon University, Lisbon, Portugal; Programme for Advanced Medical Education, Fundação Calouste Gulbenkian, Ministry of Health and Foundation for Science and Technology, Lisbon, Portugal
5 shared publications - Miguel Nobre Menezes
Structural and Coronary Heart Disease Unit, Cardio‐Oncology Unit CHULN Hospital de Santa Maria Cardiovascular Center of the University of Lisbon Lisbon Portugal
4 shared publications Miguel Nobre Menezes
Universidade de Lisboa
3 shared publicationsPedro Marques
Universidade de Lisboa
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (7)
Cardiac Resynchronization Therapy in Cardio-Oncology: Real-World Evidence of Benefit in Cancer Patients with Heart Failure
Introduction Heart failure (HF) is a major cause of morbidity and mortality among patients with cancer. The incidence of HF in this high-risk population is increasing, partly due to the cardiotoxic effects associated with contemporary cancer therapies. Despite substantial advances in oncological treatments and the growing number of cancer survivors, HF remains a major determinant of adverse clinical outcomes. Cardiac resynchronization therapy (CRT) is an established treatment that improves symptoms and reduces mortality in patients with chronic HF. However, patients [...] Introduction Heart failure (HF) is a major cause of morbidity and mortality among patients with cancer. The incidence of HF in this high-risk population is increasing, partly due to the cardiotoxic effects associated with contemporary cancer therapies. Despite substantial advances in oncological treatments and the growing number of cancer survivors, HF remains a major determinant of adverse clinical outcomes. Cardiac resynchronization therapy (CRT) is an established treatment that improves symptoms and reduces mortality in patients with chronic HF. However, patients
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (7)
Open AccessCardiac Resynchronization Therapy in Cardio-Oncology: Real-World Evidence of Benefit in Cancer Patients with Heart Failure
Introduction Heart failure (HF) is a major cause of morbidity and mortality among patients with cancer. The incidence of HF in this high-risk population is increasing, partly due to the cardiotoxic effects associated with contemporary cancer therapies. Despite substantial advances in oncological treatments and the growing number of cancer survivors, HF remains a major determinant of adverse clinical outcomes. Cardiac resynchronization therapy (CRT) is an established treatment that improves symptoms and reduces mortality in patients with chronic HF. However, patients [...] Introduction Heart failure (HF) is a major cause of morbidity and mortality among patients with cancer. The incidence of HF in this high-risk population is increasing, partly due to the cardiotoxic effects associated with contemporary cancer therapies. Despite substantial advances in oncological treatments and the growing number of cancer survivors, HF remains a major determinant of adverse clinical outcomes. Cardiac resynchronization therapy (CRT) is an established treatment that improves symptoms and reduces mortality in patients with chronic HF. However, patients
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (7)
Terapia de Ressincronização Cardíaca em Cardio-Oncologia: Evidências do Benefício no Mundo Real em Doentes com Câncer e Insuficiência Cardíaca
Introdução A insuficiência cardíaca (IC) é uma importante causa de morbilidade e mortalidade entre doentes com câncer. A incidência de IC nesta população de alto risco tem vindo a aumentar, em parte devido aos efeitos cardiotóxicos associados às terapias oncológicas contemporâneas. Apesar dos avanços substanciais no tratamento oncológico e do crescente número de sobreviventes de câncer, a IC permanece como um importante determinante de desfechos clínicos adversos. A terapia de ressincronização cardíaca (TRC) é um tratamento estabelecido que melhora os [...] Introdução A insuficiência cardíaca (IC) é uma importante causa de morbilidade e mortalidade entre doentes com câncer. A incidência de IC nesta população de alto risco tem vindo a aumentar, em parte devido aos efeitos cardiotóxicos associados às terapias oncológicas contemporâneas. Apesar dos avanços substanciais no tratamento oncológico e do crescente número de sobreviventes de câncer, a IC permanece como um importante determinante de desfechos clínicos adversos. A terapia de ressincronização cardíaca (TRC) é um tratamento estabelecido que melhora os
- 1 January 2026
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 123 (7)
Open AccessTerapia de Ressincronização Cardíaca em Cardio-Oncologia: Evidências do Benefício no Mundo Real em Doentes com Câncer e Insuficiência Cardíaca
Introdução A insuficiência cardíaca (IC) é uma importante causa de morbilidade e mortalidade entre doentes com câncer. A incidência de IC nesta população de alto risco tem vindo a aumentar, em parte devido aos efeitos cardiotóxicos associados às terapias oncológicas contemporâneas. Apesar dos avanços substanciais no tratamento oncológico e do crescente número de sobreviventes de câncer, a IC permanece como um importante determinante de desfechos clínicos adversos. A terapia de ressincronização cardíaca (TRC) é um tratamento estabelecido que melhora os [...] Introdução A insuficiência cardíaca (IC) é uma importante causa de morbilidade e mortalidade entre doentes com câncer. A incidência de IC nesta população de alto risco tem vindo a aumentar, em parte devido aos efeitos cardiotóxicos associados às terapias oncológicas contemporâneas. Apesar dos avanços substanciais no tratamento oncológico e do crescente número de sobreviventes de câncer, a IC permanece como um importante determinante de desfechos clínicos adversos. A terapia de ressincronização cardíaca (TRC) é um tratamento estabelecido que melhora os
- 2 January 2024
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (5) , 657-663
Chest Computed Tomography for Lymphoma Staging: A Wasted Opportunity for Cardiovascular Risk Stratification?
- 2 January 2024
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (5) , 657-663
Chest Computed Tomography for Lymphoma Staging: A Wasted Opportunity for Cardiovascular Risk Stratification?
- Open Access
- 22 July 2023
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 43 (1) , 35-48
Interventional cardiology in cancer patients: A position paper from the Portuguese Cardiovascular Intervention Association and the Portuguese Cardio-Oncology Study Group of the Portuguese Society of Cardiology
- 22 July 2023
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 43 (1) , 35-48
Open AccessInterventional cardiology in cancer patients: A position paper from the Portuguese Cardiovascular Intervention Association and the Portuguese Cardio-Oncology Study Group of the Portuguese Society of Cardiology
- Open Access
- 1 August 2017
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 38 (suppl_1)
P571Reduced global longitudinal myocardial deformation as a subclinical marker of cardiotoxicity in patients with breast cancer
Background: Chemotherapy (CT) or radiotherapy (RT) induced cardiotoxicity (Cx) is a clinical challenge and currently is diagnosed by the reduction of left ventricular ejection fraction (EF). However, early and even subclinical risk stratification is of particular relevance since the presence of myocardial damage influences the management and prognosis of these patients (pts).
- 1 August 2017
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 38 (suppl_1)
Open AccessP571Reduced global longitudinal myocardial deformation as a subclinical marker of cardiotoxicity in patients with breast cancer
Background: Chemotherapy (CT) or radiotherapy (RT) induced cardiotoxicity (Cx) is a clinical challenge and currently is diagnosed by the reduction of left ventricular ejection fraction (EF). However, early and even subclinical risk stratification is of particular relevance since the presence of myocardial damage influences the management and prognosis of these patients (pts).
- Open Access
- 1 January 2017
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 108 (2) , 184-186
Rare Association of two Genetic Causes of Sudden Death in a Young Survivor
- 1 January 2017
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 108 (2) , 184-186
Open AccessRare Association of two Genetic Causes of Sudden Death in a Young Survivor
- Open Access
- 1 September 2016
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 35 (9) , 485-494
Organização e implementação de uma consulta de cardio‐oncologia
- 1 September 2016
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 35 (9) , 485-494
Open AccessOrganização e implementação de uma consulta de cardio‐oncologia
- Open Access
- 1 June 2016
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 35 (6) , 331-338
Triple-site pacing for cardiac resynchronization in permanent atrial fibrillation – Acute phase results from a prospective observational study
- 1 June 2016
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 35 (6) , 331-338
Open AccessTriple-site pacing for cardiac resynchronization in permanent atrial fibrillation – Acute phase results from a prospective observational study
- 1 June 2016
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 22 (6) , 465-471
Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty
- 1 June 2016
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 22 (6) , 465-471
Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty
- 1 November 2015
- Published by Elsevier in Indian Heart Journal
- Vol. 67 (6) , 602-603
Asymptomatic chronic type A aortic dissection
- 1 November 2015
- Published by Elsevier in Indian Heart Journal
- Vol. 67 (6) , 602-603
Asymptomatic chronic type A aortic dissection